Acumen Pharmaceuticals
ABOS
96 hedge funds and large institutions have $128M invested in Acumen Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 17 closing their positions.
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
18% more capital invested
Capital invested by funds: $109M → $128M (+$19.2M)
14% more funds holding
Funds holding: 84 → 96 (+12)
2.56% more ownership
Funds ownership: 63.7% → 66.26% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.71M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.79M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.11M |
| 4 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$792K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$705K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.84M |
| 2 |
SG Americas Securities
New York
|
-$1.7M |
| 3 |
Millennium Management
New York
|
-$1.48M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.24M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.17M |
ABOS Hedge Fund Activity: Q2 2026 in Review
96 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q2 2026, worth a combined $128M — up 18% from $109M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ABOS positions and 17 closed out — a net gain of 13 holders — while 21 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $5.71M. The largest seller was Fidelity Investments, cutting an estimated $2.84M.
- 96 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q2 2026, up from 84 in Q1 2026.
- Funds reported $128M of Acumen Pharmaceuticals stock for Q2 2026, up 18% quarter-over-quarter.
- 30 funds opened new Acumen Pharmaceuticals positions in Q2 2026 and 17 closed out, a net change of +13 holders.
- The largest Acumen Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $5.71M added.
- The largest Acumen Pharmaceuticals seller in Q2 2026 was Fidelity Investments, an estimated $2.84M sold.
Based on aggregated 13F filings for Q2 2026.